A Phase 2 interventional study of Apatinib and Etoposide capsule and Apatinib in Ovarian Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-12.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing apatinib in Ovarian Neoplasms — 6 open to participants now, 6 under way, 1 of them phase 3. apatinib · Ovarian Neoplasms.
Among the 22 studies testing apatinib in Ovarian Neoplasms, this one is the 13th largest by planned enrollment, is one of 4 that started in 2020, is one of 15 in phase 2, and was the 14th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →6 of the 22 studies testing apatinib in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70 · Women only
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
The First Affiliated Hospital of Xiamen University
Ages 18–75 · Women only
Guangxi Medical University · Sites in China
Ages 18–75 · Women only
Jin Li
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is close to the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 59 across the 22 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 22 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd.: 6 open now, 6 under way, 4 of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 14th largest by planned enrollment, is one of 3 that started in 2020, is one of 3 in phase 2, and was the 7th registered.
Jiangsu HengRui Medicine Co., Ltd.’s Ovarian Neoplasms studies by the year they started, since 2015.
1 of the studies testing apatinib in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07033819Cancer Institute and Hospital, Chinese Academy of Medical SciencesNeoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib | 2027-06-20 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing apatinib in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jiangsu HengRui Medicine Co., Ltd.’s 16 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with apatinib (375 mg qd).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
Drug: Apatinib and Etoposide capsule
Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
Drug: Apatinib
Objective response rate (ORR) by investigator
ORR was defined as the proportion of subjects who have a complete or partial response relative to baseline .
Time frame: up to 2 years
AEs+SAEs
Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0
Time frame: 30 days after the last dose
PFS by investigator
PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigator according to the RECIST criteria.
Time frame: up to 2 years
Overall Survival (OS)
OS is the time interval from the date of randomization to death from any cause.
Time frame: up to 3 years
Pharmacokinetic characteristic
Evaluation of PK parameters Tmax of apatinib or etoposide in plasma
Time frame: up to 2 years
Pharmacokinetic characteristic
Evaluation of PK parameters Cmax of apatinib or etoposide in plasma
Time frame: up to 2 years
Pharmacokinetic characteristic
Evaluation of PK parameters t1/2 of apatinib or etoposide in plasma
Time frame: up to 2 years
Pharmacokinetic characteristic
Evaluation of PK parameters AUC0-t of apatinib or etoposide in plasma
Time frame: up to 2 years
No study locations are listed for this record.
Plan to share: No — All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.
Start is estimated for May 2020; primary completion for Dec 2020, 7 months later.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 7 months is below that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Apatinib · Etoposide
Jiangsu HengRui Medicine Co., Ltd. →